Completed × Waldenstrom Macroglobulinemia × Bortezomib × Clear all BDH-WM01
Phase 4 Completed
35 enrolled
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Phase 3 Completed
202 enrolled
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Phase 1/2 Completed
9 enrolled 8 charts
R2W
Phase 2 Completed
60 enrolled
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
Phase NA Completed
23 enrolled 8 charts
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia
Phase 2 Completed
59 enrolled
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)
Phase 2 Completed
63 enrolled 10 charts
VCR
Phase 2 Completed
24 enrolled 11 charts
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Phase 2 Completed
21 enrolled 10 charts
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Phase 1/2 Completed
79 enrolled 19 charts
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
Phase 2 Completed
23 enrolled 9 charts
BDR-WM
Phase 2 Completed
59 enrolled
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase 1 Completed
93 enrolled
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 Completed
18 enrolled
Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia
Phase 2 Completed
27 enrolled
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
55 enrolled
WM2
Phase 2 Completed
34 enrolled
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
Phase 1/2 Completed
107 enrolled
PS-341 in Treating Patients With Advanced Cancer
Phase 1 Completed
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
Phase 2 Completed
27 enrolled